Expert Interviews
Expert Interviews
Advertisement
Molly Li, MBBSASCO 2025 | June 12, 2025
The study participants include those who have had at least one first-degree relative diagnosed with lung cancer.
View More
Sophie Poznanski, PhDASCO 2025 | June 10, 2025
Sophie Poznanski, PhD, shares insights from her ASCO 2025 presentation on the multifunctional antibody modality.
Matthew Smeltzer, PhDASCO 2025 | June 9, 2025
The study compared results from North America with global results by high-income and low- or middle-income countries.
Cheryl Czerlanis, MDASCO 2025 | June 5, 2025
Cheryl Czerlanis, MD, shares insights from the session on lung cancer screening that she chaired at ASCO 2025.
Shriya GargASCO 2025 | June 3, 2025
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MDASCO 2025 | June 6, 2025
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Jennifer W. Carlisle, MDASCO 2025 | June 2, 2025
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Coral Olazagasti, MDConference Coverage | June 1, 2025
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Raj Bhardwaj, MDNon-Small Cell Lung Cancer | May 29, 2025
Dr. Sanjay Juneja and Dr. Eric Singhi join a special episode of DDx for a candid conversation on a real patient case.
Eric Singhi, MDConference Coverage | June 1, 2025
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Stephen V. Liu, MDConference Coverage | June 1, 2025
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Eric Singhi, MDNon-Small Cell Lung Cancer | May 23, 2025
Eric Singhi, MD, discusses the recent FDA approval and explains the associated new biomarker testing considerations.
Mara B. Antonoff, MDLung Cancer | May 21, 2025
Mara Antonoff, MD, explains the nuances of determining if a patient with oligometastatic disease is a candidate for surgery.
Cecilia BrownLung Cancer | May 15, 2025
Ravi Rajaram, MD, MSc, discusses Medicaid expansion, timely access to care, regionalization effects, and remaining questions.
Michael R. Gieske, MDLung Cancer | May 9, 2025
Michael R. Gieske, MD, discusses why Lung Cancer Action Week is a key time to promote screening and shares recent milestones.
Stephen V. Liu, MDLung Cancer | May 9, 2025
Dr. Liu discusses his experience as co-chair of the Texas Lung Cancer Conference and shares key highlights.
Alexander Spira, MD, PhDELCC 2025 | May 8, 2025
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Mara B. Antonoff, MDLung Cancer | May 6, 2025
Mara Antonoff, MD, discusses key advances and addresses common misconceptions about operating in oligometastatic disease.
Jared Weiss, MDELCC 2025 | May 2, 2025
Dr. Weiss noted the results in both feasibility and safety, particularly via injection, which had limited complications.
Mara B. Antonoff, MDLung Cancer | April 30, 2025
Dr. Mara Antonoff discusses why it's critical to offer information and updates on surgery for oligometastatic lung cancer.
Advertisement
Advertisement
Latest News

June 13, 2025